Correction to: Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Cornelius F. Waller, Julia Möbius, Adolfo Fuentes-Alburo
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsHER2/EGFR in Cancer Research · Biosimilars and Bioanalytical Methods · Monoclonal and Polyclonal Antibodies Research
Correction to: British Journal of Cancer 10.1038/s41416-020-01255-z, published online 16 February 2021
After publication of our article [1] we became aware that the Competing Interests statement was incomplete. It should read as follows: “C.F.W. is a consultant/advisory board member for Mylan Inc. A.F.-A. is a paid employee of Mylan Inc. and may hold stock with the company. J.M. is a paid employee of Mylan Healthcare GmbH in Hannover, Germany, and may hold stock with the company. Mylan Inc. produces trastuzumab for intravenous administration.”
The original article has been corrected.